Swine Patents (Class 800/17)
-
Publication number: 20070277253Abstract: The present invention relates to a novel promoter and its use in driving expression of foreign genes in transgenic animals (especially pigs). Accordingly, the present invention provides a method for producing transgenic animals harboring heterologous genes regulated by the promoter of the present invention.Type: ApplicationFiled: May 23, 2006Publication date: November 29, 2007Inventors: Teng-Kuei Winston Cheng, Shinn-Chih Wu, Chi-Chen Hsu, Yu-Sheng Lin, Chih-Jen Lin
-
Patent number: 7291764Abstract: An improved method of nuclear transfer involving the transplantation of donor differentiated pig cell nuclei into enucleated pig oocytes is provided. The resultant nuclear transfer units are useful for multiplication of genotypes and transgenic genotypes by the production of fetuses and offspring. Production of genetically engineered or transgenic pig embryos, fetuses and offspring is facilitated by the present method since the differentiated cell source of the donor nuclei can be genetically modified and clonally propagated.Type: GrantFiled: September 13, 1999Date of Patent: November 6, 2007Assignee: University of Massachusetts, a Public Institution of Higher Education of the Commonwealth of Massachusetts, as Represented by its Amherst Campus, Office of Vice Chancellor for Research at AmherstInventors: Steven L. Stice, Jose Cibelli, James Robl, Paul Golueke
-
Patent number: 7238797Abstract: The invention provides a transgenic pig having incorporated into its genome a HSP70 gene or fragment thereof, whereby the transgenic pig overexpresses HSP70. The transgenic pig of the invention can be used in the production of HSP in large quantities, as a xenograft source for transplation and as an animal model close to human for illustrating the protective roles of HSP. Furthermore, the transgenic pig of the invention has a better meat quality and exhibits an increased growth rate and a reduced backfat thickness.Type: GrantFiled: March 8, 2005Date of Patent: July 3, 2007Assignee: Animal Technology InstituteInventors: Wen-Chuan Lee, Ming-Yu Chen
-
Patent number: 7238851Abstract: The present invention features compositions (e.g, nucleic acids encoding fat-1, optionally and operably linked to a constitutively active or tissue-specific promoter or other regulatory sequence and pharmaceutically acceptable formulations including that nucleic acid or biologically active variants thereof) and methods that can be used to effectively modify the content of PUFAs in animal cells (i.e., cells other than those of C. elegants, for example, mammalian cells such as myocytes, neurons (whether of the periferal or central nervous system), adipocytes, endothelial cells, and cancer cells). The modified cells, whether in vivo or ex vivo (e.g., in tissue culture), transgenic animals containing them, and food products obtained from those animals (e.g., meat or other edible parts of the animals (e.g., liver, kidney, or sweetbreads)) are also within the scope of the present invention.Type: GrantFiled: March 12, 2002Date of Patent: July 3, 2007Assignee: The General Hospital CorporationInventor: Jing X. Kang
-
Patent number: 7232938Abstract: A method of reconstituting an animal embryo involves transferring the nucleus from a quiescent donor cell into a suitable recipient cell. The donor cell is quiescent, in that it is caused to exit from the growth and division cycle at G1 and to arrest in the G0 state. Nuclear transfer may take place by cell fusion. The reconstituted embryo may then give rise to one or more animals. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: August 11, 2004Date of Patent: June 19, 2007Assignee: Roslin InstituteInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7220718Abstract: Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.Type: GrantFiled: August 2, 2002Date of Patent: May 22, 2007Assignees: United States of America as represented by the Secretary of the Department of Health and Human Services, Virginia Tech Intellectual Properties, Inc.Inventors: Oral Alpan, Tirumalai Kamala, Polly Matzinger, William Hugold Velander
-
Patent number: 7199281Abstract: The present invention provides methods of producing transgenic livestock animals. The methods generally involve first introducing a nucleoprotein made up of nucleic acid and a recombinase into a totipotent or pluripotent cell to produce a recombinant totipotent or pluripotent cell and then growing the recombinant totipotent or pluripotent cell to produce the transgenic livestock animal. The invention further provides kits for use in generating transgenic non-human animals of the invention.Type: GrantFiled: September 6, 2002Date of Patent: April 3, 2007Assignee: The Regents of the University of CaliforniaInventors: James D. Murray, Elizabeth A. Maga, Gary B. Anderson, Stefanie M. Oppenheim
-
Patent number: 7169963Abstract: The present invention relates to animals that express exogenous growth factors in their milk, and in particular to pigs that express exogenous IGF-I in their milk. The present invention also relates to methods for increasing piglet weight gain and intestinal lactase activity. The present invention thus provides a method of facilitating piglet development and decreasing piglet mortality.Type: GrantFiled: September 30, 2003Date of Patent: January 30, 2007Assignee: Board of Trustees of the University of IllinoisInventors: Matthew B. Wheeler, Sharon M. Donovan, Gregory T. Bleck, Marcia Monaco-Siegel
-
Patent number: 7141716Abstract: The invention provides a swine which is homozygous for a major histocompatibility complex haplotype and at least 60% homozygous at all other genetic loci and such animal is propagatable, and a cell or an organ derived therefrom. The invention also provides a method for providing a swine which is homozygous at swine leukocyte antigens (SLA) A, B, C, DR, and DQ, and in which at least 60% of all other genetic loci are homozygous, as well as a method of inducing tolerance in a recipient mammal of a first species to a graft from a donor mammal of a second species.Type: GrantFiled: August 20, 2002Date of Patent: November 28, 2006Assignee: The General Hospital CorporationInventors: David H. Sachs, Scott Arn
-
Patent number: 7126039Abstract: This disclosure provides a system for generating animal tissue with carbohydrate antigens that are compatible for transplantation into human patients. The tissue is inactivated homozygously for expression of ?(1,3)galactosyltransferase, and comprises a transgene for ?(1,2)fucosyltransferase. As a result, cell-surface N-acetyl lactosamine is not converted to the Gal?(1,3)Gal xenoantigen. Instead, it is converted to Fuc?(1,2)Gal, which is H substance, a self-antigen in humans. The tissue may also contain A or B-transferase, which will cause H substance to be converted into other ABO blood group antigens for compatibility with patients of the same blood type. This invention improves transplant compatibility of the xenograft tissue by lessening the risk of reactions resulting from xenoantigen and unconverted N-acetyl lactosamine acceptor determinants.Type: GrantFiled: March 21, 2002Date of Patent: October 24, 2006Assignee: Geron CorporationInventors: Chris Denning, A. John Clark, J. Michael Schiff
-
Patent number: 7115795Abstract: The invention provides a transgenic animal having within its genome a transgene construct for gastrointestinal tract specific expression of a protein. In a preferred embodiment, the protein is a phytase or a homologue thereof. Such proteins may be heterologous and may be specifically expressed in the salivary gland of the animal by operably linking the nucleic acid sequence encoding the protein with regulatory sequence including a salivary gland protein promoter/enhancer. Also provided are methods of expressing and producing proteins using such nucleic acid constructs. Further, antibodies specific to such proteins and immunological diagnostic kits are also provided.Type: GrantFiled: April 20, 2000Date of Patent: October 3, 2006Assignee: University of GuelphInventors: Cecil W. Forsberg, Serguei Golovan, John P. Phillips
-
Patent number: 7115796Abstract: The invention provides a transgenic pig having incorporated into its genome a HSP70 gene or fragment thereof, whereby the transgenic pig overexpresses HSP70. The transgenic pig of the invention can be used in the production of HSP in large quantities, as a xenograft source for transplantation and as an animal model close to human for illustrating the protective roles of HSP. Furthermore, the transgenic pig of the invention has a better meat quality and exhibits an increased growth rate and a reduced backfat thickness.Type: GrantFiled: January 24, 2003Date of Patent: October 3, 2006Assignee: Animal Technology InstituteInventors: Bor-Show Tzang, Ching-Fu Tu, Wen-Chuan Lee, Ming-Yu Chen, San-Yuan Huang, Jyh-Hung Lin
-
Patent number: 7087808Abstract: The present invention discloses a method for expressing multiple recombinant proteins in transgenic non-human mammalian milk, characterized in which human clotting factor IX gene and porcine lactoferrin gene are transferred into the mammal by gene injection and embryonic implantation to obtain expression in the milk of transgenic mammal and its filial generation. The method of this invention can maintain the stable expression of multiple recombinant proteins in the transgenic mammal during lactation and stable expression amount proximate to that of the first generation in the offsprings of the transgenic non-human mammal.Type: GrantFiled: March 3, 2004Date of Patent: August 8, 2006Assignee: Animal Technology Institute TaiwanInventors: Shinn Chih Wu, Teng Kuei Cheng, Chuan Mu Chen, Shau Ping Lin, Chon Ho Yen, Ping Cheng Yang
-
Patent number: 7067713Abstract: The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression.Type: GrantFiled: January 31, 2001Date of Patent: June 27, 2006Assignee: Pharming Intellectual Property B.V.Inventors: Jan Henricus Nuijens, Henricus Antonius Van Veen, Frank Robert Pieper, Joris Jan Heus
-
Patent number: 7045677Abstract: A process for the production of a peptide is disclosed, the process comprising expressing in the milk of a transgenic, non-human, placental mammal a fusion protein which comprises the peptide to be expressed linked to a fusion partner protein which is lysozyme. The fusion protein may be separate from the milk and cleaved to yield the target peptide. A transgenic, non-human, placental mammal whose genome incorporates a DNA molecule comprising a coding sequence encoding lysozyme coupled to a peptide is also described.Type: GrantFiled: December 21, 2001Date of Patent: May 16, 2006Assignee: Pharming Intellectual Property BVInventors: Ian Robert Cottingham, Graham Edward McCreath
-
Patent number: 7041870Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: GrantFiled: November 30, 2001Date of Patent: May 9, 2006Assignees: Medarex, Inc., Kirin Brewery Company LimitedInventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
-
Patent number: 7038107Abstract: Porcine nucleic acid sequences flanking potentially infectious porcine endogenous retroviral (PERV) insertion sites have been identified and isolated. The unique flanking sequences include porcine nucleic acid sequences that flank the 3? end and porcine nucleic acid sequences that flank the 5? end of PERV insertion sites. The present invention provides compositions and methods for detecting presence of PERV in a sample, particularly those with infectious potential. In addition, the invention relates to breeding of pigs or selection of porcine tissue that is free of infectious PERV for use as a xenotransplant tissue.Type: GrantFiled: March 28, 2002Date of Patent: May 2, 2006Assignee: Mayo Foundation for Medical Education and ResearchInventors: Cunqi Cui, Lisa E. Diamond, John S. Logan
-
Patent number: 7030289Abstract: The present invention relates to the stabilization of milk from transgenic animals. In particular, the invention relates to the protection of proteins (e.g. fibrinogen) expressed in milk from transgenic animals by co-expression of a serine proteinase inhibitor (e.g., ?1-antitrypsin) in the milk of the transgenic animals.Type: GrantFiled: May 18, 2001Date of Patent: April 18, 2006Assignee: PPL Therapeutics (Scotland) LtdInventors: Ian Robert Cottingham, Graham Edward McCreath
-
Patent number: 6987211Abstract: The present invention relates to novel alternative forms of human acetylcholinesterase (AChE) and nucleotide sequences encoding the same. The genes encoding the novel forms of human AChE have been identified in various malignant tumor cells. In a further aspect, the invention relates to a transgenic animal assay system for evaluating efficacy of drugs against cholinergic proteins, prior to or in the course of therapeutic treatment. Transgenic animals, preferably developing tadpole of Xenopus or mice which express human AChE, are used. The transgenic animal assay system is also useful for evaluating the toxicity of substances which potentially block human AChE (e.g. organophosphorous compounds).Type: GrantFiled: May 12, 1999Date of Patent: January 17, 2006Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Hermona Soreq, Haim Zakut, Moshe Shani
-
Patent number: 6984772Abstract: A transgenic, non-human mammalian animal is capable of expressing a heterologous gene for human or other recombinant physiologically functional fibrinogen holoprotein or individual subunit chain polypeptides thereof or a modified or fusion fibrinogen in mammary glands of the animals and secreting the expressed product into a body fluid. Methodology employing such a mammal yields recombinant physiologically functional fibrinogens, subunit chain polypeptides thereof, and modified or fusion fibrinogens.Type: GrantFiled: May 17, 1995Date of Patent: January 10, 2006Assignees: Virginia Tech Intellectual Properties, Inc., American Red Cross, The University of North Carolina at Chapel HillInventors: William H. Velander, William N. Drohan, Henryk Lubon, John L. Johnson
-
Patent number: 6906238Abstract: The present invention provides methods of producing a cloned non-human mammalian nuclear transfer (NT) embryo and methods for producing a cloned non-human mammal. Embodiments of the methods include introducing donor genetic material into a metaphase I oocyte; introducing donor genetic material into a non-enucleated oocyte; introducing donor genetic material obtained from a donor cell that is at metaphase into an oocyte; introducing donor genetic material into an oocyte, and naturally activating the oocyte or the NT embryo; and introducing donor genetic material obtained from a donor cell that is at late G1 phase into an oocyte.Type: GrantFiled: March 15, 2001Date of Patent: June 14, 2005Assignee: University of Georgia Research Foundation, Inc.Inventor: Steven Stice
-
Patent number: 6891082Abstract: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject.Type: GrantFiled: April 24, 2001Date of Patent: May 10, 2005Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra C. McPherron
-
Patent number: 6888047Abstract: The invention relates to recombinant DNA constructs, a method for producing a recombinant biologically active protein in vivo in the urine of a non-human mammal using a kidney-specific promoter, such as the uromodulin promoter, and the transgenic non-human mammals that serve as urine-based bioreactors for protein production.Type: GrantFiled: June 26, 2000Date of Patent: May 3, 2005Assignee: New York UniversityInventors: Xue-Ru Wu, Tung-Tien Sun
-
Patent number: 6872868Abstract: Genetic transformation of a zygote and the embryo and mature organism which result therefrom is obtained by placing or inserting exogenous genetic material into the nucleus of the zygote or into any genetic material which ultimately forms at least a part of the nucleus of the zygote. It is preferred that the exogenous genetic material be added to a pronuclei of the zygote and is particularly preferred that it be added to the male pronucleus of the zygote. Thereafter, the zygote is allowed to undergo differentiation and development into the organism. The genotype of the zygote and the organism which results therefrom will include the genotype of the exogenous genetic material and the exogenous genetic material will be phenotypically expressed. The invention can be utilized in a variety of ways including, for example, animal and plant breeding to modify or create new species, it can be used in epigenetics and in the understanding and treatment of genetic diseases.Type: GrantFiled: May 24, 1995Date of Patent: March 29, 2005Assignee: Ohio UniversityInventors: Thomas E. Wagner, Peter C. Hoppe
-
Publication number: 20040268424Abstract: The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.Type: ApplicationFiled: August 21, 2003Publication date: December 30, 2004Inventor: Carol J. Phelps
-
Publication number: 20040261138Abstract: Genetic markers in the porcine melanocortin-4 receptor (MC4R) gene are disclosed which are associated with favorable meat quality traits including, drip loss, marbling, pH and color. Further, novel sequence data from regions of the gene are disclosed which may be used in a PCR test to screen for the presence of the marker. The genetic marker may be used to screen animals for breeding purposes which have the desired traits. Kits which take advantage of the PCR test are also disclosed.Type: ApplicationFiled: April 1, 2004Publication date: December 23, 2004Applicant: Iowa State University Research Foundation, Inc.Inventors: Max F. Rothschild, Kwan Suk Kim, Rebecca S. Emnett
-
Publication number: 20040250305Abstract: The subject invention relates to a method of transferring a specific immune response into a cloned animal. In this manner, one may create a specific, selective, secondary immune response in an otherwise immunologically naïve animal.Type: ApplicationFiled: September 4, 2003Publication date: December 9, 2004Inventors: Zuhair A. Latif, Sean F. Nowlan
-
Patent number: 6825395Abstract: This invention provides transgenic mammals other than man carrying the gene of the human complement inhibitor (DAF/CD55) and expressing the human complement inhibitor in their organs and tissues, particularly in their endothelial cells. This invention provides nonhuman transgenic mammals useful as laboratory animals in the medical and pharmacological fields and/or sources of organs, tissues, cells and the like for medical treatment of man.Type: GrantFiled: April 5, 2000Date of Patent: November 30, 2004Assignee: Nippon Meat Packers, Inc.Inventors: Hiroshi Murakami, Tatsuya Fujimura, Yoichi Takahagi, Koji Toyomura, Tamotsu Shigehisa
-
Publication number: 20040199934Abstract: Transgenic rats are generated which incorporate a primate B1 bradykinin receptor transgene(s) into their genome. This B1 bradykinin receptor gene is expressed in these transgenic rats, which results in binding of compounds which are selective for the primate form (such as the human form) of the receptor and not the rat form of the receptor. Therefore, the expressed transgenes within these transgenic lines mimic antagonist and agonist selectivity of the wild type primate B1 bradykinin receptor. These transgenic animals are useful as a specific receptor occupancy model for modulators of the B1 bradykinin receptor from the human or closely related species, as well as providing for an animal model system for assessment of the pharmacodynamic properties of such a B1 bradykinin modulator(s).Type: ApplicationFiled: February 19, 2004Publication date: October 7, 2004Inventors: John W Hess, Robert I Gould, Douglas J Pettibone
-
Publication number: 20040194159Abstract: An improved method of nuclear transfer involving the transplantation of donor differentiated pig cell nuclei into enucleated pig oocytes is provided. The resultant nuclear transfer units are useful for multiplication of genotypes and transgenic genotypes by the production of fetuses and offspring. Production of genetically engineered or transgenic pig embryos, fetuses and offspring is facilitated by the present method since the differentiated cell source of the donor nuclei can be genetically modified and clonally propagated.Type: ApplicationFiled: April 2, 2004Publication date: September 30, 2004Applicant: University of MassachusettsInventors: Steven L. Stice, James M. Robl, Jose Cibelli, Paul Golueke
-
Publication number: 20040180041Abstract: Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.Type: ApplicationFiled: March 25, 2004Publication date: September 16, 2004Applicant: University of MassachusettsInventors: Steven L. Stice, Jose Cibelli, James M. Robl
-
Publication number: 20040177395Abstract: The subject invention relates to a method of creating a cloned animal having the precise immunological response and capabilities as the founder animal.Type: ApplicationFiled: March 11, 2004Publication date: September 9, 2004Inventor: Zuhair A. Latif
-
Publication number: 20040177394Abstract: The subject invention relates to a method of transferring a specific immune response into a cloned animal. In this manner, one may create a specific, selective, secondary immune response in an otherwise immunologically naïve animal.Type: ApplicationFiled: March 11, 2004Publication date: September 9, 2004Inventor: Zuhair A. Latif
-
Publication number: 20040166578Abstract: The invention provides an in vitro culture medium for in vitro-produced porcine embryo for the in vitro culture thereof, which can improve the quality of the resulting blastocyst and can raise the ratio of the development into fetus and infant after transfer, along with a method for in vitro culturing in vitro-produced porcine embryo using the culture medium, which can improve the quality of the resulting blastocyst and can develop the blastocyst into fetus and infant after transfer.Type: ApplicationFiled: March 2, 2004Publication date: August 26, 2004Applicant: National Institute of Agrobiological SciencesInventors: Kazuhiro Kikuchi, Hiroyuki Kaneko, Junko Noguchi
-
Publication number: 20040161735Abstract: A method for the cryopreservation of oocytes or embryos, which comprises centrifugation of oocytes or embryos to polarize cytoplasmic lipid outside the oocyte or embryonic cells, subjecting the oocytes or embryos to low temperature conditions in the presence of a cryoprotectant which results in freezing of the oocytes or embryos prior to lipid depolarization, followed by low temperature storage of the frozen lipid polarized oocytes or embryos are described, as are oocytes and embryos produced according to such methods, and methods for producing live animals.Type: ApplicationFiled: February 13, 2004Publication date: August 19, 2004Applicants: THE UNIVERSITY OF QUEENSLAND, BRESAGEN LIMITEDInventors: Mark Brenton Nottle, Ranald Cameron, Luke Francis Sharkerley Beebe, Alan Weaver Blackshaw, Hiroshi Nagashima
-
Publication number: 20040163140Abstract: A graftable animal cell or tissue of a donor species for use in medicine expresses, or is capable of being caused to express, increased amounts of endogenous complement regulatory molecules for preventing activation of complement in a recipient species. Such tissue or organs are useful for xenotransplantation. Porcine complement regulatory proteins CD59, DAF have been sequenced. Also disclosed are methods of inducing in an animal cell or tissue resistance protection against complement attack.Type: ApplicationFiled: January 20, 2004Publication date: August 19, 2004Applicant: UNIVERSITY OF WALES COLLEGE OF MEDICINEInventors: Bryan Paul Morgan, Neil Kevin Rushmere, Stewart James Hinchliffe, Carmen Wilma Van Den Berg
-
Publication number: 20040154048Abstract: Methods for the activation of nuclear transferred embryos using elevated calcium levels introduced into cells, and a maturation promoting factor (MPF) inhibitor are described. Elevated calcium levels introduced into the embryo cells from a culture medium containing elevated calcium levels, in the range 2 mM to about 12 mM, followed directly and immediately by incubation with DMAP are described. Also described are animals produced from embryos so treated.Type: ApplicationFiled: March 22, 2004Publication date: August 5, 2004Inventors: Christopher Gerald Grupen, Mark Brenton Nottle
-
Publication number: 20040110292Abstract: Methods for the production of nuclear transfer embryos, nuclear transfer embryos and animals derived therefrom are described. The method generally comprises at least the steps of: providing at least one enucleated recipient cell; providing at least one donor cell or nucleus; providing a fusion media which is substantially free of calcium; placing said at least one enculeated recipient cell and at least one donor cell or nucleus in contact with one another to form couplets; and, fusing via electrofusion in said fusion media said at least one recipient cell with at least one donor cell or nucleus to form a nuclear transfer embryo.Type: ApplicationFiled: February 23, 2004Publication date: June 10, 2004Inventors: Andrew Craig Boquest, Christopher Gerald Grufen, Mark Brenton Nottle
-
Publication number: 20040098756Abstract: The present invention concerns transgenic vertebrates that are useful in expressing proteins and in producing antibodies. The present invention discloses methods for producing vertebrates that are transgenic for a bacteriophage RNA polymerase. The present invention further discloses methods for the use of such transgenic vertebrates in protein expression and in antibody production.Type: ApplicationFiled: October 29, 2003Publication date: May 20, 2004Inventor: Sujay Singh
-
Publication number: 20040093624Abstract: The present invention relates to a method of improving development potential of an embryo, embryos developed therefrom and organisms resulting from embryos developed from the method. In a first aspect of the present invention, there is provided a method of culturing an embryo to improve development potential, said method comprising; obtaining an embryo; and culturing the embryo to enhance trophectoderm development of the embryo. The method relates to improving the chances of an embryo implanting to result in a successful pregnancy. The embryos desirably become implantation competent favouring foetal-maternal interaction and development to term of an embryo. The trophectoderm stimulating agent may be any compound which is proven to stimulate normal trophectoderm development. Preferably the agent is fibroblast growth factor-4 (FGF4) protein.Type: ApplicationFiled: June 5, 2003Publication date: May 13, 2004Inventors: Andrew James French, Robert Daniels
-
Publication number: 20040083498Abstract: A method is described of selecting a porcine oocyte or a population of oocytes with improved developmental competence following either in vitro or in vivo maturation.Type: ApplicationFiled: April 14, 2003Publication date: April 29, 2004Inventors: Paul Alexandre DeSousa, Timothy James King, Ian Wilmut, Jie Zhu
-
Patent number: 6727405Abstract: A DNA sequence containing a gene encoding a protein, the gene being under the transcriptional control in the DNA sequence of a mammalian milk protein promoter which does not naturally control the transcription of the gene, such DNA sequence including DNA enabling secretion of the protein.Type: GrantFiled: May 19, 1994Date of Patent: April 27, 2004Assignee: Genzyme CorporationInventors: Katherine Gordon, Suzanne Groet, Lothar Hennighausen, Heiner Westphal
-
Publication number: 20040073963Abstract: This invention provides a nonhuman transgenic mammal carrying transgene comprising the regulatory genes capable of functioning in the hyperacute rejection-occurring local cells and gene encoding human N-acetylglucosaminyltransferase III (GnT-III), or a nonhuman transgenic mammal carrying transgene comprising the regulatory genes and genes encoding GnT-III and the human complement inhibitor. Because of reduced &agr;-Gal antigens in the hyperacute rejection-occurring local cells or because of both reduced &agr;-Gal antigens and expression of the human complement inhibitor, the transgenic mammal of this invention can effectively inhibit the hyperacute rejection caused by discordant xenotransplantation. Consequently, this invention provides the transgenic mammal suitable for organ transplantation.Type: ApplicationFiled: February 25, 2003Publication date: April 15, 2004Inventors: Hiroshi Murakami, Tatsuya Fujimura, Yoichi Takahagi, Koji Toyomura, Tamotsu Shigehisa
-
Publication number: 20040073021Abstract: The genes encoding for the porcine beta-1 and beta-2 chains of the porcine interleukin-12 receptor have been cloned. The complete sequence of complementary DNA of both chains has been determined. Variants have been found associated with superior cellular immunity. Applications of the novel molecules are discussed.Type: ApplicationFiled: November 3, 2003Publication date: April 15, 2004Inventors: Federico A. Zuckermann, William Schnitzlein
-
Publication number: 20040068760Abstract: The invention features novel methods for the production of large quantities of xenogenous antibodies, such as human antibodies. Preferably, this result is effected by inactivation of IgM heavy chain expression and, optionally, by inactivation of Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of xenogenous antibodies (e.g., non-bovine antibodies), preferably human antibodies.Type: ApplicationFiled: May 19, 2003Publication date: April 8, 2004Inventors: James M. Robl, Philippe Collas, Eddie Sullivan, P. Kasinathan, Richard A. Goldsby, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida
-
Publication number: 20040055027Abstract: A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-8 (GDF-8) chromosomally integrated into the germ cells of the animal is provided. Also provided are methods for making such animals, and methods of treating animals, including humans, with antibodies or antisense directed to GDF-8. The animals so treated are characterized by increased muscle tissue and bone content.Type: ApplicationFiled: June 17, 2003Publication date: March 18, 2004Applicant: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra C. McPherron
-
Publication number: 20040053379Abstract: The present invention relates to a method for the production of unsaturated fatty acids with at least two double bonds and/or a method for the production of triglycerides with an increased content of polyunsaturated fatty acids with at least two double bonds. The invention furthermore relates to the advantageous use of the nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 18 in the method and for generating a transgenic organism, preferably a transgenic plant or a transgenic microorganism, with an increased content of fatty acids, oils or lipids with unsaturated C18-, C20-, or C22-fatty acids.Type: ApplicationFiled: July 2, 2003Publication date: March 18, 2004Inventors: Jens Lerchl, Andreas Renz, Ernst Heinz, Frederic Domergue, Ulrich Zahringer
-
Publication number: 20040055025Abstract: The present invention provides a method and materials for reproducing an immune response of a mammal against one or more antigens of interest. The method preferably involves cloning a founder mammal and producing an immune response in the clone that is substantially identical to the immune response of the founder animal to the antigen or antigens of interest. Accordingly, a source of valuable antibodies can be maintained despite the death or illness of the antibody producing animal.Type: ApplicationFiled: January 30, 2003Publication date: March 18, 2004Applicant: Infigen, Inc.Inventors: Erik J. Forsberg, Gregory H. Leno, Jeffrey Betthauser, Kenneth Eilertsen, Michael D. Bishop
-
Patent number: 6706947Abstract: The invention relates to an animal model of cancer. The animal carries a tumour xenograft and is immunosuppressed by administration of cyclosporin and ketoconazole. The model is useful for studying cancer and treatment thereof.Type: GrantFiled: September 30, 2002Date of Patent: March 16, 2004Assignee: Fremantle HospitalInventor: John Harvey Turner
-
Patent number: 6700037Abstract: The present invention relates to materials and methods for cloning porcine animals. The invention relates in part to totipotent cells useful for cloning porcine animals, porcine embryos produced from such cells by employing nuclear transfer techniques, and porcine animals that arise from such cells and embryos.Type: GrantFiled: December 28, 2000Date of Patent: March 2, 2004Assignee: Infigen, Inc.Inventors: Philip Damiani, Jeffrey M. Betthauser, Erik J. Forsberg, Michael D. Bishop